Pear Therapeutics, Inc.

Thimble Point Acquisition Corp. (Nasdaq: THMA) was a healthcare-focused blank-check company that completed its initial public offering in 2021. The SPAC announced a definitive business combination with Pear Therapeutics, Inc. in June 2021, targeting the digital therapeutics segment of the broader healthcare and medtech sector. Pear Therapeutics developed FDA-authorized prescription digital therapeutics for conditions including substance use disorder and insomnia. The transaction closed in December 2021, with the combined company listing on Nasdaq under the ticker PEAR. Pear Therapeutics subsequently filed for Chapter 11 bankruptcy protection in January 2023, and the deal is now classified as closed. Sign up at SpacDesk for full filings, deal analytics, and historical data on THMA and thousands of other SPAC transactions.

SPAC Counterparty (1)